ID

12252

Descripción

An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072 Treatments given for an adverse event should be recorded on the appropriate “Adverse event” page. Treatments given for prophylaxis or treatment of abnormal laboratory values (e.g. blood cells, potassium supplements, etc.) should be recorded on this page. List any treatments continuing at screen or that have begun since screen (or medical procedures performed) that are not recorded on Adverse event pages.

Palabras clave

Versiones (2)

1. 30/9/15 30/9/15 -
2. 28/10/15 28/10/15 -

Subido en

28 de octubre de 2015

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia